Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation

Thomas A Mavrakanas; David M Charytan

doi:10.34067/KID.0003002022

Apixaban versus No Anticoagulation by P2Y12 Inhibitor Prescription Status in Dialysis Patients with Atrial Fibrillation

Kidney360. 2022 Aug 1;3(10):1769-1771. doi: 10.34067/KID.0003002022. eCollection 2022 Oct 27.

Authors

Thomas A Mavrakanas¹, David M Charytan²

Affiliations

¹ Division of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
² Nephrology Division, Department of Medicine, New York University Langone Medical Center, New York, New York.

Abstract

In patients with atrial fibrillation on dialysis, the incidence of stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription.In patients with atrial fibrillation on dialysis who were on a P2Y12 inhibitor, apixaban increased the risk of bleeding, compared with no anticoagulation.The incidence of myocardial infarction or ischemic stroke was similar with apixaban or no anticoagulation, regardless of P2Y12 prescription status.

Keywords: P2Y12 inhibitor; apixaban; atrial fibrillation; bleeding; dialysis; prescriptions; stroke.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Atrial Fibrillation* / complications
Humans
Prescriptions
Pyridones / adverse effects
Renal Dialysis / adverse effects

Substances

apixaban
Pyridones